Browsing by Autor "Keri Yang"

Now showing 1 - 3 of 3

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting
(Future Medicine, 2025) Bijal Shah; Mei Xue; Wesley Furnback; Keri Yang
In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma
(Taylor & Francis, 2026) Javier Pinilla-Ibarz; Mei Xue; Elizabeth Wu; Kaitlyn Esselman; Wesley Furnback; Swetha Challagulla; Keri Yang
Zanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs acalabrutinib and ibrutinib in 1L and 2L.
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia
(Taylor & Francis, 2026) Sikander Ailawadhi; Swetha Challagulla; Po-Ya Chuang; Wesley Furnback; Keri Yang
This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.